Riversedge Advisors’s CorMedix CRMD Stock Holding History

Riversedge Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,373	Closed	-$32K	–	69
2022 Q3	$32K	Hold	11,373	–	–	0.01%	73
2022 Q2	$46K	Hold	11,373	–	–	0.02%	66
2022 Q1	$62K	Hold	11,373	–	–	0.02%	67
2021 Q4	$52K	Sell	11,373 -2,886	-20%	-$14.3K	0.02%	64
2021 Q3	$66K	Hold	14,259	–	–	0.02%	66
2021 Q2	$98K	Hold	14,259	–	–	0.04%	53
2021 Q1	$142K	Hold	14,259	–	–	0.06%	46
2020 Q4	$106K	Hold	14,259	–	–	0.05%	49
2020 Q3	$86K	Hold	14,259	–	–	0.05%	45
2020 Q2	$90K	Buy	14,259 +2,739	+24%	+$12.7K	0.05%	43
2020 Q1	$41K	Hold	11,520	–	–	0.04%	32
2019 Q4	$84K	Buy	+11,520	New	+$70.4K	0.1%	35

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Riversedge Advisors's CRMD Position: Q4 2022 in Review

Riversedge Advisors sold out of CorMedix (CRMD) in Q4 2022, closing a stake of 11,373 shares — an estimated $32K sold.

Riversedge Advisors first reported a position in CRMD in Q4 2019 and held it in 12 quarters. The position peaked at $142K in Q1 2021. 65 funds tracked by Wall St. Rank hold CRMD as of Q4 2022.

Riversedge Advisors reported no remaining CorMedix position as of Q4 2022 after selling out during the quarter.
Riversedge Advisors sold 11,373 CorMedix shares in Q4 2022, an estimated $32K.
Riversedge Advisors first reported a position in CorMedix in Q4 2019 and held it in 12 quarters.
Riversedge Advisors's CorMedix position peaked at $142K in Q1 2021.
65 funds tracked by Wall St. Rank held CorMedix as of Q4 2022.

Based on Riversedge Advisors's 13F filing for Q4 2022, filed 20 Jan 2023.